Matches in Wikidata for { <http://www.wikidata.org/entity/Q100158691> ?p ?o ?g. }
Showing items 1 to 32 of
32
with 100 items per page.
- Q100158691 description "clinical trial" @default.
- Q100158691 description "ensayu clínicu" @default.
- Q100158691 description "klinisch onderzoek" @default.
- Q100158691 description "клінічне випробування" @default.
- Q100158691 description "կլինիկական փորձարկում" @default.
- Q100158691 name "A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of COVID-19 Vaccine in Healthy Adults" @default.
- Q100158691 name "A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of COVID-19 Vaccine in Healthy Adults" @default.
- Q100158691 type Item @default.
- Q100158691 label "A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of COVID-19 Vaccine in Healthy Adults" @default.
- Q100158691 label "A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of COVID-19 Vaccine in Healthy Adults" @default.
- Q100158691 prefLabel "A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of COVID-19 Vaccine in Healthy Adults" @default.
- Q100158691 prefLabel "A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of COVID-19 Vaccine in Healthy Adults" @default.
- Q100158691 P1132 Q100158691-11e6755a-4e3a-22f2-7b33-9692b7b262b5 @default.
- Q100158691 P1476 Q100158691-48ba28e2-435d-a56f-ba87-5b3237ace303 @default.
- Q100158691 P17 Q100158691-94de5fa2-4432-9889-8adb-abf210635398 @default.
- Q100158691 P2888 Q100158691-a7b8e64b-4d25-4710-f646-21473384bb82 @default.
- Q100158691 P31 Q100158691-b560f2a4-42ec-4fe9-1c04-f927a8bfa112 @default.
- Q100158691 P580 Q100158691-3fe57431-487f-e942-05c8-3666a68cec35 @default.
- Q100158691 P582 Q100158691-604a1cfc-43c5-1bf3-9b26-c0024d5c9b0d @default.
- Q100158691 P6099 Q100158691-4bcae178-4eb0-3809-fd58-f72a5f343ecf @default.
- Q100158691 P6099 Q100158691-929aa168-4bf1-e0ee-bf3f-abbd0c4ade0d @default.
- Q100158691 P7019 Q100158691-68BAD76C-767D-41D1-804E-52F7D02C6B79 @default.
- Q100158691 P1132 "+280" @default.
- Q100158691 P1476 "A randomized, observer-blind, placebo-controlled, Phase I/II study to evaluate the safety, reactogenicity and immunogenicity of Receptor Binding Domain (RBD) SARS-CoV-2 (COVID-19) Hepatitis B surface antigen (HBsAg) virus like particle (VLP) Vaccine in Healthy Adults" @default.
- Q100158691 P17 Q408 @default.
- Q100158691 P2888 ACTRN12620000817943.aspx @default.
- Q100158691 P31 Q30612 @default.
- Q100158691 P580 "2020-08-17T00:00:00Z" @default.
- Q100158691 P582 "2021-03-30T00:00:00Z" @default.
- Q100158691 P6099 Q42824440 @default.
- Q100158691 P6099 Q5452194 @default.
- Q100158691 P7019 "380145" @default.